Paloma Partners Management CO Fibrogen Inc Transaction History

Paloma Partners Management CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$18.57 - $35.68 $264,845 - $508,868	-14,262 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$31.0 - $55.72 $442,122 - $794,678	14,262 New	14,262 $495,000
Q1 2020 May 15, 2020	SELL	$23.3 - $45.96 $421,287 - $831,002	-18,081 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$34.58 - $48.06 $90,668 - $126,013	2,622 Added 16.96%	18,081 $775,000
Q3 2019 Nov 14, 2019	BUY	$36.98 - $48.45 $571,673 - $748,988	15,459 New	15,459 $571,000
Q2 2018 Aug 14, 2018	SELL	$44.9 - $64.95 $560,935 - $811,420	-12,493 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$45.35 - $61.65 $322,619 - $438,578	7,114 Added 132.26%	12,493 $577,000
Q4 2017 Feb 14, 2018	BUY	$41.95 - $60.1 $225,649 - $323,277	5,379	5,379 $255,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Paloma Partners Management CO, based on Form 13F filings with the SEC.

Stay updated on Paloma Partners Management CO with notifications on news.